Chemokine (CXC motif) ligand 9 serum levels in mixed cryoglobulinaemia are associated with circulating levels of IFN-gamma and TNF-alpha

Clinical and Experimental Rheumatology

Volumn 30, Issue 6, 2012, Pages 864-870

  Antonelli, A ^a   Fallahi, P ^a   Ferrari, S M ^a   Corrado, A ^a   Sebastiani, M ^b   Manfredi, A ^b   Frascerra, S ^a   Miccoli, M ^a   Zignego, A L ^c   Ferrannini, E ^a   Ferri, C ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Chemokine; Cryoglobulinaemia; CXCL10; CXCL9; Cytokine; Hepatitis C; IFN ; TNF

Indexed keywords

AMINOTRANSFERASE; CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTHRALGIA; ARTHRITIS; ARTICLE; CONTROLLED STUDY; CRYOGLOBULINEMIA; DISEASE DURATION; FEMALE; HEPATITIS C; HUMAN; INFECTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PURPURA; RAYNAUD PHENOMENON; SEROLOGY; SJOEGREN SYNDROME; TH1 CELL; VASCULITIS; WEAKNESS;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CXCL9; CHI-SQUARE DISTRIBUTION; CRYOGLOBULINEMIA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VASCULITIS;

EID: 84872741617     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. LIAO F, RABIN RL, YANNELLI JR, KONIARIS LG, VANGURI P, FARBER JM. Human Mig chemokine: biochemical and functional characterization. J Exp Med 1995; 182: 1301-14.
2. ROMAGNANI P, ANNUNZIATO F, LASAGNI L et al.. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 2001; 107: 53-63.
3. BONECCHI R, BIANCHI G, BORDIGNON PP et al.. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187: 129-34.
4. WRIGHT TM, FARBER JM. 5' regulatory region of a novel cytokine gene mediates selective activation by interferon gamma. J Exp Med 1991; 173: 417-22.
5. LACOTTE S, BRUN S, MULLER S, DUMORTIER H. CXCR3, inflammation, and autoimmune diseases. Ann N Y Acad Sci 2009; 1173: 310-7.
6. MELTER M, EXENI A, REINDERS ME et al.. Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001; 104: 2558-64.
7. HANCOCK WW, LU B, GAO W et al.. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192: 1515-20.
8. HANCOCK WW, GAO W, CSIZMADIA V, FAIA KL, SHEMMERI N, LUSTER AD. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001; 193: 975-80.
9. SIMPSON JE, NEWCOMBE J, CUZNER ML, WOODROOFE MN. Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol 2000; 26: 133-42.
10. GOEBELER M, TOKSOY A, SPANDAU U, ENGELHARDT E, BRÖCKER EB, GILLITZER R. The C-X-C chemokine Mig is highly expressed in the papillae of psoriatic lesions. J Pathol 1998; 184: 89-95.
11. PATEL DD, ZACHARIAH JP, WHICHARD LP. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 2001; 98: 39-45.
12. KOGA S, AUERBACH MB, ENGEMAN TM, NOVICK AC, TOMA H, FAIRCHILD RL. T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-gamma-induced chemokine Mig. J Immunol 1999; 163: 4878-85.
13. ANTONELLI A, ROTONDI M, FALLAHI P et al.. High levels of circulating CXCL10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 2004; 89: 5496-9.
14. ANTONELLI A, ROTONDI M, FALLAHI P et al.. Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 2005; 152: 171-7.
15. ANTONELLI A, FERRI C, FALLAHI P et al.. High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol 2008; 103: 2488-94.
16. ANTONELLI A, FERRI C, FERRARI SM et al.. Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection. J Rheumatol 2010; 37: 91-7.
17. ANTONELLI A, FERRI C, FALLAHI P et al.. CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C. Dig Liver Dis 2009; 41: 42-8.
18. ANTONELLI A, FERRI C, FALLAHI P et al.. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine 2008; 42: 137-43.
19. ANTONELLI A, FERRI C, FALLAHI P et al.. Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. Metabolism 2008; 57: 1270-7.
20. ANTONELLI A, FERRI C, FERRARI SM, COLACI M, FALLAHI P. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun Rev 2008; 8: 18-23.
21. BUTERA D, MARUKIAN S, IWAMAYE AE et al.. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005; 106: 1175-82.
22. WASMUTH HE, LAMMERT F, ZALDIVAR MM et al.. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 2009; 137: 309-19, 319.e1-3.
23. ZEREMSKI M, DIMOVA R, BROWN Q, JACOBSON IM, MARKATOU M, TALAL AH. Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virusinfection. J Infect Dis 2009; 200: 1774-80.
24. MOURA AS, CARMO RA, TEIXEIRA AL, LEITE VH, ROCHA MO. Soluble inflammatory markers as predictors of liver histological changes in patients with chronic hepatitis C virus infection. Eur J Clin Microbiol Infect Dis 2010; 29: 1153-61.
25. WAN L, KUNG YJ, LIN YJ et al.. Th1 and Th2 cytokines are elevated in HCV-infected SVR(-) patients treated with interferon-alpha. Biochem Biophys Res Commun 2009; 379: 855-60.
26. HELBIG KJ, RUSZKIEWICZ A, LANFORD RE et al.. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro. J Virol 2009; 83: 836-46.
27. BIÈCHE I, ASSELAH T, LAURENDEAU I et al.. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 2005; 332: 130-44.
28. VITALI C, BOMBARDIERI S, JONSSON R et al.. European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
29. FERRI C, SEBASTIANI M, GIUGGIOLI D et al.. Mixed cryoglobulinemia: Demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33: 355-74.
30. TAKEUCHI M, OH-I K, SUZUKI J et al.. Elevated serum levels of CXCL9/monokine induced by interferon-gamma and CXCL10/ interferon-gamma-inducible protein-10 in ocular sarcoidosis. Invest Ophthalmol Vis Sci 2006; 47: 1063-8.
31. PANZER U, STEINMETZ OM, REINKING RR et al.. Compartment-specific expression and function of the chemokine IP-10/CXCL10 in a model of renal endothelial microvascular injury. J Am Soc Nephrol 2006; 17: 454-64.
32. OGAWA N, PING L, ZHENJUN L, TAKADA Y, SUGAI S. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome. Arthritis Rheum 2002; 46: 2730-41.
33. YOON KC, PARK CS, YOU IC et al.. Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest Ophthalmol Vis Sci 2010; 51: 643-50.
34. ANTONELLI A, FERRARI SM, FRASCERRA S et al.. Peroxisome proliferator-activated receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytes. Mol Cell Endocrinol 2012; 349: 255-61.
35. ANTONELLI A, FERRARI SM, FRASCERRA S et al.. Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab 2011; 96: 1859-63.
36. ANTONELLI A, FERRARI SM, FRASCERRA S et al.. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes. J Clin Endocrinol Metab 2010; 95: E413-20.
37. ANTONELLI A, FERRARI SM, FALLAHI P et al.. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2009; 94: 1803-9.
38. ANTONELLI A, FALLAHI P, ROTONDI M et al.. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur J Endocrinol 2006; 154: 651-8.
39. FERRI C. Mixed cryoglobulinemia. Orphanet J Rare Dis 2008; 3: 25.
40. ABEL G, ZHANG QX, AGNELLO V. Hepatitis C virus infection in type II mixed cryoglobulinemia. Arthritis Rheum 1993; 36: 1341-9.
41. FERRI C, LA CIVITA L, LONGOMBARDO G, GRECO F, BOMBARDIERI S. Hepatitis C virus and mixed cryoglobulinaemia. Eur J Clin Invest 1993; 23: 399-405.
42. GOREVIC PD, KASSAB HJ, LEVO Y et al.. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69: 287-308.
43. FRANCIOTTA D, MARTINO G, ZARDINI E et al.. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001; 115: 192-8.
44. GANGUR V, SIMONS FE, HAYGLASS KT. Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses. FASEB J 1998; 12: 705-13.
45. ANTONELLI A, ROTONDI M, FERRARI SM et al.. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J Clin Endocrinol Metab 2006; 91: 614-20.
46. REALDON S, PONTISSO P, ADAMI F et al.. High levels of soluble tumor necrosis factor superfamily receptors in patients with hepatitis C virus infection and lymphoproliferative disorders. J Hepatol 2001; 34: 723-9.
47. SAADOUN D, BOYER O, TRÉBEDEN-NÈGRE H et al.. Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis. J Hepatol 2004; 41: 1031-7.
48. LOFFREDA S, MURATORI P, MURATORI L, MELE L, BIANCHI FB, LENZI M. Enhanced monocyte Th1 cytokine production in HCVinfected cryoglobulinemic patients. J Hepatol 2003; 38: 230-6.